HK1225730B - (2s)-n-[(1s)-1-氰基-2-苯基乙基]-1，4-氧雜氮雜環庚烷-2-甲酰胺作為二肽基肽酶i抑制劑 - Google Patents

(2s)-n-[(1s)-1-氰基-2-苯基乙基]-1，4-氧雜氮雜環庚烷-2-甲酰胺作為二肽基肽酶i抑制劑

Info

Publication number
HK1225730B
HK1225730B HK16114117A HK16114117A HK1225730B HK 1225730 B HK1225730 B HK 1225730B HK 16114117 A HK16114117 A HK 16114117A HK 16114117 A HK16114117 A HK 16114117A HK 1225730 B HK1225730 B HK 1225730B
Authority
HK
Hong Kong
Prior art keywords
oxazepane
carboxamides
phenylethyl
cyano
inhibitors
Prior art date
Application number
HK16114117A
Other languages
English (en)
Inventor
Hans Roland LÖNN
Stephen Connolly
Steven Swallow
Staffan Po Karlsson
Carl-Johan Aurell
John Fritiof Pontén
Kevin James Doyle
De Poël Amanda Jane Van
Graham Peter Jones
David Wyn Watson
Jaqueline Anne Macritchie
Nicholas John Palmer
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52432834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1225730(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1225730B publication Critical patent/HK1225730B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epoxy Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
HK16114117A 2014-01-24 2016-12-12 (2s)-n-[(1s)-1-氰基-2-苯基乙基]-1，4-氧雜氮雜環庚烷-2-甲酰胺作為二肽基肽酶i抑制劑 HK1225730B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461931090P 2014-01-24 2014-01-24

Publications (1)

Publication Number Publication Date
HK1225730B true HK1225730B (zh) 2017-09-15

Family

ID=52432834

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16114117A HK1225730B (zh) 2014-01-24 2016-12-12 (2s)-n-[(1s)-1-氰基-2-苯基乙基]-1，4-氧雜氮雜環庚烷-2-甲酰胺作為二肽基肽酶i抑制劑
HK18114946.6A HK1255870A1 (zh) 2014-01-24 2018-11-22 作為二肽基肽酶 i 抑制劑的(2S)-N-[(1S)-1-氰基-2-苯基乙基]-1，4-氧雜氮雜環庚烷-2-甲醯胺

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18114946.6A HK1255870A1 (zh) 2014-01-24 2018-11-22 作為二肽基肽酶 i 抑制劑的(2S)-N-[(1S)-1-氰基-2-苯基乙基]-1，4-氧雜氮雜環庚烷-2-甲醯胺

Country Status (37)

Country Link
US (16) US9522894B2 (zh)
EP (3) EP3744714A1 (zh)
JP (5) JP6469711B2 (zh)
KR (1) KR102417684B1 (zh)
CN (2) CN110483492B (zh)
AP (1) AP2016009322A0 (zh)
AR (1) AR099177A1 (zh)
AU (4) AU2015208932C1 (zh)
BR (1) BR112016016224B1 (zh)
CA (1) CA2935625C (zh)
CL (1) CL2016001889A1 (zh)
CR (1) CR20160327A (zh)
CY (2) CY1120049T1 (zh)
DK (2) DK3097086T3 (zh)
DO (1) DOP2016000175A (zh)
EA (1) EA032794B1 (zh)
ES (2) ES2658516T3 (zh)
HK (2) HK1225730B (zh)
HR (2) HRP20180116T1 (zh)
HU (2) HUE052421T2 (zh)
IL (3) IL246614B (zh)
LT (2) LT3097086T (zh)
MX (1) MX368840B (zh)
MY (1) MY194850A (zh)
NO (1) NO2699580T3 (zh)
NZ (2) NZ722063A (zh)
PE (1) PE20161218A1 (zh)
PH (1) PH12016501439B1 (zh)
PL (2) PL3323814T3 (zh)
PT (2) PT3323814T (zh)
RS (2) RS56919B1 (zh)
SG (2) SG11201606052TA (zh)
SI (2) SI3323814T1 (zh)
TW (1) TWI690517B (zh)
UY (1) UY35963A (zh)
WO (1) WO2015110826A1 (zh)
ZA (2) ZA201605856B (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (zh) 2014-01-24 2018-02-24
US20180028541A1 (en) * 2016-07-29 2018-02-01 Astrazeneca Ab Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors for treating bronchiectasis
US20190247400A1 (en) * 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating granulomatosis with polyangiitis
EP3758708A1 (en) 2018-03-01 2021-01-06 AstraZeneca AB Pharmaceutical compositions comprising (2s)--{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
US20210322438A1 (en) * 2018-07-17 2021-10-21 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
JP2021530513A (ja) * 2018-07-17 2021-11-11 インスメッド インコーポレイテッド 炎症性腸疾患を処置するための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド
CN111689923B (zh) * 2019-03-12 2022-11-08 中国科学院上海药物研究所 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途
JP2022553549A (ja) * 2019-10-23 2022-12-23 チョン クン ダン ファーマシューティカル コーポレーション 慢性閉塞性肺疾患（ｃｏｐｄ）の予防または治療用の組成物
EP4182700A1 (en) * 2020-07-20 2023-05-24 Insmed Incorporated Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions
CN115996923A (zh) 2020-08-26 2023-04-21 四川海思科制药有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN114159446A (zh) * 2020-09-11 2022-03-11 中国科学院上海营养与健康研究所 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用
MX2023006194A (es) 2020-12-04 2023-06-09 Reistone Biopharma Company Ltd Inhibidor de molecula peque?a de catepsina c y uso medicinal del mismo.
WO2022140516A1 (en) * 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CA3207466A1 (en) * 2021-02-05 2022-08-11 Lingyun Wu Fused ring derivatives containing 1,4-oxazepane
AU2022376535A1 (en) * 2021-10-29 2024-05-02 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
WO2023134656A1 (zh) * 2022-01-11 2023-07-20 上海壹典医药科技开发有限公司 一种肽基腈类化合物及其应用
WO2023159120A1 (en) * 2022-02-16 2023-08-24 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa
WO2023160542A1 (zh) * 2022-02-22 2023-08-31 四川海思科制药有限公司 二肽基肽酶抑制剂化合物的盐及晶型
WO2023160541A1 (zh) * 2022-02-22 2023-08-31 四川海思科制药有限公司 一种含氮杂环化合物的制备方法
TW202333739A (zh) * 2022-02-22 2023-09-01 大陸商四川海思科製藥有限公司 二肽基肽酶1抑制劑多晶型物及其製備方法和用途
CN114644562B (zh) * 2022-04-29 2023-08-22 常州大学 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用
WO2023236877A1 (zh) * 2022-06-07 2023-12-14 瑞石生物医药有限公司 苯并[c]色满化合物的可药用盐、其多晶型及用途
TW202404960A (zh) * 2022-06-07 2024-02-01 大陸商瑞石生物醫藥有限公司 苯并［ｃ］色滿化合物的多晶型及其製備方法和用途
WO2024008680A1 (en) 2022-07-06 2024-01-11 Chiesi Farmaceutici S.P.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
WO2024081889A1 (en) 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
WO2024088307A1 (zh) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2782151B2 (ja) 1993-07-16 1998-07-30 博 吉田 衝撃吸収柵用の端ストッパ
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
DK1317555T3 (da) 2000-09-08 2008-03-25 Prozymex As Dipeptidylpeptidase i krystalstruktur og anvendelser heraf
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
PL370766A1 (en) 2001-12-04 2005-05-30 F.Hoffmann-La Roche Ag Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
ATE399763T1 (de) 2003-05-30 2008-07-15 Prozymex As Proteasehemmer
JP2006527704A (ja) * 2003-06-18 2006-12-07 プロザイメックス・アクティーゼルスカブ プロテアーゼ阻害剤
PT2206728T (pt) 2004-04-07 2018-04-17 Rinat Neuroscience Corp Métodos de tratamento da dor associada ao cancro ósseo através da administração de um anticorpo antagonista do fator de crescimento nervoso
US20070286854A1 (en) 2004-04-28 2007-12-13 Bayer Healthcare Ag Diagnostics And Therapeutics For Diseases Associated With Dipeptidyl-Peptidase 1 (Dpp1)
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
CN1976678B (zh) 2004-06-29 2010-06-02 奈康明丹麦有限责任公司 水不溶性药快速释放药物组合物的制造方法及通过本方法得到的药物组合物
US20090054358A1 (en) 2004-07-19 2009-02-26 The John Hopkins University Flt3 inhibitors for immune suppression
SI3248600T1 (sl) 2005-02-18 2020-09-30 Abraxis Bioscience, Llc Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija
WO2007005668A2 (en) 2005-06-30 2007-01-11 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
EP2139887A2 (en) 2007-03-07 2010-01-06 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
TW200916447A (en) 2007-08-29 2009-04-16 Methylgene Inc Sirtuin inhibitors
US20100282247A1 (en) 2007-09-25 2010-11-11 Novartis Ag Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
EA201000958A1 (ru) * 2007-12-12 2010-12-30 Астразенека Аб Пептидилнитрилы и их применение в качестве ингибиторов дипептидилпептидазы i
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
MX2011006108A (es) 2008-12-08 2011-11-18 Vm Pharma Llc Composiciones de inhibidores de los receptores tirosina quinasa.
BRPI1016132B8 (pt) 2009-04-01 2021-05-25 Bial Portela & Ca Sa composição, formulação farmacêutica, processo de obtenção de uma formulação farmacêutica estável
CN102574830A (zh) * 2009-05-07 2012-07-11 阿斯利康(瑞典)有限公司 取代的1-氰基乙基杂环基甲酰胺化合物750
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
HUE056525T2 (hu) 2010-04-07 2022-02-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása
WO2011154677A1 (en) * 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
IT1404036B1 (it) 2010-12-17 2013-11-08 Oto Melara Spa Veicolo armato con struttura migliorata.
SG192669A1 (en) 2011-02-11 2013-09-30 Glaxosmithkline Ip Dev Ltd Cathepsin c inhibitors
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
AU2013224421B2 (en) 2012-02-21 2017-03-02 Merck Patent Gmbh 8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors
US9328118B2 (en) 2012-04-17 2016-05-03 Astellas Pharma Inc. Nitrogen-containing bicyclic aromatic heterocyclic compound
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
EP2775304A1 (en) 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
WO2014140091A1 (en) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
WO2014140081A1 (en) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
US8871783B2 (en) 2013-03-14 2014-10-28 Boehringer Ingelheim International Gmbh Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin C
CN108707140B (zh) 2013-03-14 2022-07-22 勃林格殷格翰国际有限公司 蛋白酶c抑制剂
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
EA029030B1 (ru) 2013-09-09 2018-01-31 Прозюмекс А/С Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i
WO2015032942A1 (en) 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
NO2699580T3 (zh) 2014-01-24 2018-02-24
MX2016014921A (es) 2014-05-15 2017-07-28 Insmed In Incorporated Metodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
EP3149192B1 (en) 2014-05-30 2019-01-02 Versitech Limited Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers
JP6529575B2 (ja) 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
EA031376B1 (ru) 2014-09-12 2018-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Спироциклические ингибиторы катепсина с
CA2965566A1 (en) 2014-11-14 2016-05-19 Boehringer Ingelheim International Gmbh Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists
JP6783426B2 (ja) 2015-03-05 2020-11-11 ニュープロザイム・セラピューティクス・アンパルトセルスカブＮｅｕｐｒｏｚｙｍｅ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡｐＳ ジペプチジルペプチダーゼｉ阻害剤としてのペプチジルニトリル化合物
US20180028541A1 (en) 2016-07-29 2018-02-01 Astrazeneca Ab Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors for treating bronchiectasis
US20190247400A1 (en) * 2018-02-07 2019-08-15 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating granulomatosis with polyangiitis
EP3758708A1 (en) 2018-03-01 2021-01-06 AstraZeneca AB Pharmaceutical compositions comprising (2s)--{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
US20210322438A1 (en) 2018-07-17 2021-10-21 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
JP2021530513A (ja) 2018-07-17 2021-11-11 インスメッド インコーポレイテッド 炎症性腸疾患を処置するための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド
AU2020289560A1 (en) 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
WO2022140516A1 (en) 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
WO2022232420A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
CA3215375A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis

Also Published As

Publication number Publication date
SI3323814T1 (sl) 2020-10-30
PH12016501439A1 (en) 2017-02-06
HUE038274T2 (hu) 2018-10-29
IL246614B (en) 2018-02-28
LT3323814T (lt) 2020-10-26
HUE052421T2 (hu) 2021-04-28
AU2015208932B8 (en) 2017-03-09
PL3097086T3 (pl) 2018-04-30
JP7157791B2 (ja) 2022-10-20
JP6469711B2 (ja) 2019-02-13
US20210238152A1 (en) 2021-08-05
US11673872B2 (en) 2023-06-13
JP6804570B2 (ja) 2020-12-23
TWI690517B (zh) 2020-04-11
IL265611A (en) 2019-05-30
MX368840B (es) 2019-10-18
SI3097086T1 (en) 2018-04-30
US11667615B2 (en) 2023-06-06
US10669245B2 (en) 2020-06-02
LT3097086T (lt) 2018-02-26
AU2018202956B2 (en) 2019-05-09
US20200247765A1 (en) 2020-08-06
SG10201701056QA (en) 2017-03-30
EA201691375A1 (ru) 2017-01-30
US20230278969A1 (en) 2023-09-07
RS60639B1 (sr) 2020-09-30
US11680049B2 (en) 2023-06-20
MX2016009349A (es) 2016-10-13
US9815805B2 (en) 2017-11-14
ES2658516T3 (es) 2018-03-12
AP2016009322A0 (en) 2016-07-31
EP3323814B1 (en) 2020-05-13
BR112016016224A2 (zh) 2017-08-08
US20230069044A1 (en) 2023-03-02
KR102417684B1 (ko) 2022-07-05
US20200017455A1 (en) 2020-01-16
AU2017200338B2 (en) 2018-03-01
CN110483492A (zh) 2019-11-22
IL252836A0 (en) 2017-08-31
EA032794B1 (ru) 2019-07-31
US9522894B2 (en) 2016-12-20
NZ722063A (en) 2017-09-29
US11673871B2 (en) 2023-06-13
CR20160327A (es) 2016-10-20
HK1255870A1 (zh) 2019-08-30
JP7336563B2 (ja) 2023-08-31
US11117874B2 (en) 2021-09-14
AU2018202956A1 (en) 2018-05-17
US20230028726A1 (en) 2023-01-26
WO2015110826A1 (en) 2015-07-30
AU2015208932A1 (en) 2016-07-28
AU2015208932B2 (en) 2017-02-16
EP3744714A1 (en) 2020-12-02
US11655223B2 (en) 2023-05-23
AU2017200338A1 (en) 2017-02-02
AU2019202675A1 (en) 2019-05-16
US10287258B2 (en) 2019-05-14
US11655222B2 (en) 2023-05-23
CN105980367A (zh) 2016-09-28
US20230250071A1 (en) 2023-08-10
JP2017503832A (ja) 2017-02-02
US11655224B2 (en) 2023-05-23
HRP20180116T1 (hr) 2018-03-23
CA2935625C (en) 2022-10-18
ZA201800431B (en) 2019-09-25
CY1123391T1 (el) 2021-12-31
DK3097086T3 (en) 2018-02-05
PT3323814T (pt) 2020-08-05
CA2935625A1 (en) 2015-07-30
ZA201605856B (en) 2020-02-26
EP3097086A1 (en) 2016-11-30
KR20160111470A (ko) 2016-09-26
PT3097086T (pt) 2018-02-21
US11773069B2 (en) 2023-10-03
JP2021046423A (ja) 2021-03-25
BR112016016224B1 (pt) 2023-02-23
JP2023156479A (ja) 2023-10-24
EP3097086B1 (en) 2017-12-13
US20230025351A1 (en) 2023-01-26
DOP2016000175A (es) 2016-08-15
AR099177A1 (es) 2016-07-06
PH12016501439B1 (en) 2017-02-06
US20180251436A1 (en) 2018-09-06
NZ734768A (en) 2022-09-30
CY1120049T1 (el) 2018-12-12
US20230033573A1 (en) 2023-02-02
CN105980367B (zh) 2019-08-23
JP2019070029A (ja) 2019-05-09
PL3323814T3 (pl) 2020-10-19
RS56919B1 (sr) 2018-05-31
UY35963A (es) 2015-07-31
CL2016001889A1 (es) 2016-12-09
US11814359B2 (en) 2023-11-14
US20230085620A1 (en) 2023-03-23
US20230062646A1 (en) 2023-03-02
US20230115170A1 (en) 2023-04-13
NO2699580T3 (zh) 2018-02-24
AU2015208932C1 (en) 2017-05-25
AU2015208932A8 (en) 2017-03-09
AU2019202675B2 (en) 2020-05-28
EP3323814A1 (en) 2018-05-23
ES2808060T3 (es) 2021-02-25
US20230116721A1 (en) 2023-04-13
DK3323814T3 (da) 2020-08-03
CN110483492B (zh) 2023-07-21
US20170057938A1 (en) 2017-03-02
PE20161218A1 (es) 2016-11-27
HRP20201147T1 (hr) 2020-12-11
SG11201606052TA (en) 2016-08-30
MY194850A (en) 2022-12-19
TW201612167A (en) 2016-04-01
JP2022096662A (ja) 2022-06-29
US20150210655A1 (en) 2015-07-30
US11655221B2 (en) 2023-05-23

Similar Documents

Publication Publication Date Title
IL265611A (en) (S2)–N–[S)1)–1–cyano–2–phenylethanyl]–1,4–oxazaphene–2–carboxamides as dipeptidyl peptidase 1 inhibitors
IL277167B (en) Cyclopropylamines as lsd1 inhibitors
IL277299B (en) Cyclopropylamines as lsd1 inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
HK1226398A1 (zh) 作為midh1抑制劑的苯並咪唑-2-胺
DK3265452T3 (en) Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors